Kodiak Sciences Inc

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Kodiak Sciences reports strong clinical progress and eyes market expansion

Kodiak Sciences Inc showcased strong clinical progress with positive Phase III results and plans to advance all 3 programs into Phase III studies in 2024.
The company's focus on durability, diverse pipeline, and strategic approach position them well in addressing retinal vascular diseases.
While facing challenges in differentiation and long-term efficacy demonstration, Kodiak has opportunities to expand market reach through innovative study designs and patient subgroup exploration.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.

Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates

PALO ALTO, Calif. , Nov. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023.

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study. With 6-month dosing of all patients, tarcocimab and the ABC platform continue to demonstrate differentiated durability.

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

PALO ALTO, Calif. , Nov. 1, 2023 /PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 3-6 in San Francisco.

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

PALO ALTO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON study in retinal vein occlusion (RVO), and the primary results and new analyses from the Phase 3 GLEAM and GLIMMER studies in diabetic macular edema (DME), will be shared at the 56th Annual Scientific Meeting of The Retina Society, being held from Oct 11 – 14 in New York, United States.

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

PALO ALTO, Calif. , Sept. 8, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023, at 12:55 p.m.

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year After 4 initiating doses in the first 6 months, approximately half of tarcocimab-treated patients required no additional injections in the second 6 months Low and comparable rates of cataract adverse events were observed (tarcocimab 4.9% vs aflibercept 2.8%) These results provide additional supportive evidence for the development of Kodiak's ABC Platform and platform-derived medicines PALO ALTO, Calif. , Sept. 7, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:  KOD) today announced top-line, one-year (48 weeks) results for its ABC Platform based investigational therapy tarcocimab tedromer 5 mg from the pivotal BEACON study in patients with macular edema due to retinal vein occlusion (RVO).

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD

Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.

Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus

PALO ALTO, Calif. , Aug. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2023.

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Kodiak Sciences (KOD) Ahead of Earnings?

Galera Therapeutics

GlaxoSmithKline

We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.

3 Biotech Stocks Poised to Beat Q2 Earnings Estimates

Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.

Kodiak (KOD) Down as Late-Stage DME Studies Fail

Kodiak Sciences shares fell by more than 45% after the biopharmaceutical company announced that it was discontinuing its tarcocimab program for eye disorders. The company's decision comes as its Phase 3 studies for its novel antibody biopolymer conjugate tarcocimab tedromer in patients with diabetic macular edema failed to meet their primary efficacy endpoints.

Kodiak Sciences discontinues development of eye disorder therapeutic; shares plummet

Kodiak Sciences (NASDAQ: KOD ) stock is falling hard on Monday after the company released results from a series of Phase 3 clinical trials. Those trials covered the use of its tarcocimab tedromer antibody as a treatment for wet AMD and DME.

Why Is Kodiak Sciences (KOD) Stock Down 58% Today?

Kodiak Sciences Inc decided to discontinue development of its experimental drug to treat a type of eye disorder, sending its shares tumbling 40% in premarket trading on Monday.

Kodiak Sciences scraps development of eye disorder drug

Shares of Kodiak Sciences Inc. KOD, +2.97% plummeted 56.9% into record-low territory, and to pace all premarket declines, after the California-based biotechnology company said it decided to discontinue development of wet age-related macular degeneration (AMD) treatment tarcocimab. The decision comes after tarcocimab failed to meet primary efficacy endpoints in two studies of patients on longer treatment intervals, with an unexpected increase in cataracts observed over time.

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

PALO ALTO, Calif. , July 24, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD) announced today topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate.

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?

Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?

PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 7, 2023, 1:30 PM ET (10:30 AM PT), New York, New York Goldman Sachs 44 th Annual Global Healthcare Conference, June 14, 2023, 7:40 PM ET (4:40 PM PT), Dana Point, California A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.

Kodiak Sciences to Present at Upcoming Investor Conferences

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.

Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition

Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up

PALO ALTO, Calif. , May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2023.

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?

PALO ALTO, Calif. , April 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that multiple scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, being held from April 23 – 27 in New Orleans, United States.

News for Kodiak Sciences Inc Stock (KOD)